drugset / Trial / NCT02652377
EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients
Phase 1
Completed
100 enrolled
Enanta Pharmaceuticals, Inc
Novotech (Australia) Pty Limited · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV) and in treatment-naive subjects with GT1/3 chronic hepatitis C (CHC) infection.
Timeline
- Start
- 2016-01-10
- Primary completion
- 2016-12-27
- Completion
- 2016-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EDP-494 | Unknown | 10 mg | Oral |
| Subject | EDP-494 | Unknown | 100 mg | Oral |
| Subject | EDP-494 | Unknown | 200 mg | Oral |